A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer - JBCRG-M03

JBCRG(Japan Breast Cancer Research Group)0 个研究点目标入组 46 人开始时间: 2013年11月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Active infection or fever at risk of infection 2.History of serious drug allergies 3.Spontanous serious renal damage or liver dysfunction(jaundice) 4.Iinterstitial pneumonia or pulmonary fibrosis by chest X-ray 5.Large pleural effusion or ascites requiring repeat drainage 6.Concurrent uncontrolled hypertension or diabetes mellitus 7.Systemic administration of steroid drug 8.Pregnant females or females of child-bearing potential 9.Concurrent active other malignancy 10.Metachronous or spontaneous bilateral breast cancer except ductal carcinoma in situ 11.Clinically important mental disorder or history of central nervous system damage 12.Clinically significant central nervous system metastases 13.Concurrent enrollment of other clinical trial 14.History use of eribulin 15.Reccurence in conserving breast or local recurrence that is appropriate therapy to reoperate 16.HBs antigen positive 17.Not suitable for participation with any other reasons (including rapid progression disease, life threatening status if not successfully treated)

发起方

JBCRG(Japan Breast Cancer Research Group)